In this article:
- Company Overview
- Stock Performance
- Market Position and Sector
- Governance and Leadership
- Key Financial Data
- FAQ
- Conclusion
- Disclaimer
- Announcement
Company Overview
Becton, Dickinson and Company, commonly referred to as BD, is a global medical technology firm headquartered in Franklin Lakes, New Jersey. Founded in 1897, the company designs, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. BD operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, each addressing critical needs in healthcare delivery and research.
The BD Medical segment focuses on products such as intravenous (IV) catheters, needle-free connectors, infusion systems, and drug delivery devices. BD Life Sciences develops solutions for specimen collection, microbiology diagnostics, and flow cytometry. The BD Interventional segment provides surgical instruments, grafts, and critical care products. These offerings serve healthcare institutions, clinical laboratories, and pharmaceutical companies worldwide.
Stock Performance
BDX shares currently trade at USD 193.585, marking a daily gain of 1.985 points or +1.03601%. This change reflects investor confidence following stable operational performance. The trading range over the past year rests between USD 163.33 and USD 251.99, signaling moderate volatility within the healthcare sector. For long-term holders, this range provides insight into potential price movement boundaries.
Market capitalization stands at approximately USD 55.49 billion, positioning BD among the larger publicly traded healthcare companies listed on the New York Stock Exchange. The last declared annual dividend is USD 4.16 per share, offering an income component alongside potential capital appreciation. This dividend signals management’s ongoing commitment to returning value to shareholders.
Trading volume in the latest session is reported at 72,314 shares, which is notably lower than the average volume of 2,323,479 shares. Such deviations can indicate shifts in investor focus or temporary market quiet.
Market Position and Sector
BD operates in the Medical – Instruments & Supplies industry, within the broader healthcare sector. This space is characterized by high regulatory oversight, stable long-term demand, and a need for ongoing innovation. BD’s offerings support both acute care and long-term medical environments, giving them diversified exposure across multiple markets.
The company competes alongside other global medical technology firms and benefits from entrenched customer relationships due to the critical nature of its products.
Governance and Leadership
The current Chief Executive Officer is Thomas E. Polen Jr., who guides strategic direction, product portfolio development, and operational efficiency. Leadership plays a central role in steering BD through regulatory requirements, supply chain management, and market expansion initiatives. Under Polen’s tenure, BD continues to emphasize technology-driven healthcare solutions and sustainable financial policies, such as consistent dividends.
Key Financial Data
- Share Price: USD 193.585
- Market Cap: USD 55,486,778,586
- Dividend: USD 4.16 annually
- 52-week Range: USD 163.33 – USD 251.99
- Daily Change: +1.985 (+1.03601%)
- Volume: 72,314 shares
- Average Volume: 2,323,479 shares
- Exchange: New York Stock Exchange (NYSE)
- ISIN: US0758871091
- CUSIP: 075887109
- IPO Date: February 21, 1973
These data points help investors assess liquidity, volatility, and the income profile of the stock. The combination of a strong market capitalization with a steady dividend indicates resilience and consistent earnings power.
FAQ
- What is BD’s annual dividend? BD pays USD 4.16 per share annually, typically in quarterly installments.
- Where is BD traded? BD is listed on the New York Stock Exchange under ticker BDX.
- How many employees does BD have? BD employs approximately 70,000 people worldwide.
- When was BD’s IPO? BD went public on February 21, 1973.
- What industry does BD operate in? BD operates in the Medical – Instruments & Supplies industry.
Conclusion
Becton, Dickinson and Company continues to demonstrate stability through a balanced combination of price performance, reliable dividends, and market presence in a critical sector. The recent upward movement in the share price reinforces its appeal to income-focused and growth-oriented investors. Monitoring volume trends and sector developments will be key for stakeholders considering adjustments to their positions.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should conduct independent research and consider professional guidance before making any investment decisions.
Announcement
For full information about the company, see the link below.
https://www.bd.com